Blue Earth Diagnostics
Clinical trials sponsored by Blue Earth Diagnostics, explained in plain language.
-
Which PET tracer shows prostate cancer recurrence better?
Diagnosis CompletedThis study compared two radioactive tracers, piflufolastat (18F) and flotufolastat (18F), used in PET scans to detect prostate cancer that has returned after surgery. The main goal was to see which tracer produces less radioactivity in the bladder, which can interfere with image …
Phase: PHASE4 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Jul 15, 2026 00:00 UTC
-
New PET tracer aims to spot prostate cancer more clearly
Diagnosis CompletedThis early-phase trial tested a new radioactive imaging agent called rhPSMA-7.3 (18F) in 24 people: some healthy volunteers and some with prostate cancer. The goal was to check safety and see how the agent spreads in the body and how well it lights up cancer on PET scans. The stu…
Phase: PHASE1 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
Sharper eye on prostate cancer: new imaging agent could spot recurrence early
Diagnosis CompletedThis phase 3 study tested a new radioactive imaging agent, rhPSMA-7.3 (18F), in 391 men with suspected prostate cancer recurrence after initial treatment. The agent is used during a PET scan to highlight cancer cells. The goal was to see how well it detects where the cancer has r…
Phase: PHASE3 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC